Beta-MSH: brain hormone that controls appetite and body weight
A natural hormone made in the human brain that reduces appetite and regulates body weight by acting on the same pathway targeted by obesity drugs like Setmelanotide; used as a research tool.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
β-MSH (beta-melanocyte-stimulating hormone) is a 22-amino-acid peptide hormone produced in the human brain and pituitary from a larger precursor protein called proopiomelanocortin (POMC). It is one of several "melanocortin" peptides the body makes from POMC, alongside the better-known α-MSH, ACTH, and β-endorphin. Unlike α-MSH, β-MSH is not made in the brains of rats or mice — a quirk of rodent genetics — which means its importance in humans went underappreciated for decades. Today it is recognized as a genuine regulator of body weight and food intake acting through the melanocortin-4 receptor (MC4R), the same central pathway that drugs like setmelanotide and bremelanotide target (Ericson and colleagues 2017; Kirwan and colleagues 2018).
History
The sequences of the melanocortin peptides — ACTH, α-MSH, and β-MSH — were first described in the 1950s, but human β-MSH was long treated with skepticism. For decades it was assumed to be an artefact of extraction: a 22-amino-acid fragment of β-lipotropin (β-LPH) that appeared in early isolations simply because the tissue had been damaged during processing (Bertagna and colleagues 1986). The debate was partly resolved by Bertagna and colleagues (1986), who identified a shorter 18-amino-acid form, h β-MSH-(5–22), in human hypothalami and non-pituitary tumors — but not in pituitary tissue — establishing that it is a genuine maturation product of POMC processing in non-pituitary human tissues. The biochemical reason rodents do not make it was clarified in reviews by Ericson and colleagues (2017) and Harno and colleagues (2018): the dibasic Lys-Lys cleavage site required for the prohormone convertase to release β-MSH from γ-lipotropin is present in human POMC but absent in the rat and mouse sequences. That species gap meant most mechanistic work bypassed β-MSH entirely until human-specific peptide quantification studies brought it back into focus. Harrold and colleagues (2003) demonstrated that β-MSH is regulated by nutritional state in rat hypothalamus, and Kirwan and colleagues (2018) used quantitative mass spectrometry to show that human hypothalamic neurons produce β-MSH at levels roughly equimolar to desacetyl α-MSH. A decisive demonstration of physiological relevance came in 2006, when Lee and colleagues identified a missense variant in the POMC gene (Tyr221Cys) that disrupts β-MSH function and co-segregated with severe, early-onset obesity in human families.
What it does
β-MSH acts primarily as an agonist at the melanocortin-4 receptor (MC4R) in the hypothalamus, where its binding suppresses appetite and promotes energy expenditure. The MC4R is expressed in key hypothalamic nuclei — the ventromedial, dorsomedial, arcuate, and paraventricular nuclei — that collectively regulate feeding behavior and energy balance (Mountjoy and colleagues 1994). When β-MSH engages MC4R, it activates G-protein signaling that ultimately reduces food intake and increases the sense of satiety. Harrold and colleagues (2003) showed that incubation of rat brain slices with β-MSH significantly increased G-protein-coupled receptor activation across those same hypothalamic regions. In animals food-restricted to create an energy deficit, hypothalamic β-MSH levels rose while α-MSH concentrations were unchanged, suggesting β-MSH plays a distinct, hunger-responsive role. Kirwan and colleagues (2018) found that leptin — the satiety hormone secreted by fat cells — stimulates production of both desacetyl α-MSH and β-MSH in cultured human hypothalamic neurons, placing β-MSH firmly within the leptin–melanocortin axis. Beyond appetite, MC4R signaling also influences sexual function; the receptor contributes to pro-erectile and pro-sexual desire effects, which is why synthetic MC4R agonists such as bremelanotide have been developed for sexual dysfunction. Separately, Panaro and colleagues (2014) found that MC4R is expressed in intestinal enteroendocrine L cells and regulates the release of the satiety hormones PYY and GLP-1, suggesting a peripheral gut component to melanocortin signaling that may also involve β-MSH.
Evidence
- Human: Lee and colleagues (Cell Metabolism, 2006) identified the POMC Tyr221Cys variant in 5 of 538 unrelated obese patients; the variant was significantly enriched relative to the general UK Caucasian population and co-segregated with obesity, hyperphagia, and increased linear growth — a phenotype matching MC4R deficiency. Kirwan and colleagues (Molecular Metabolism, 2018) directly detected β-MSH in human hypothalamic neurons using quantitative mass spectrometry, at concentrations approximately equimolar to desacetyl α-MSH, and showed leptin stimulation significantly increases its production. Chen and colleagues (JCEM, 2015) demonstrated in a randomized placebo-controlled crossover study that activation of MC4R with the synthetic agonist RM-493 (the precursor compound to setmelanotide) increases resting energy expenditure in obese individuals, establishing that the MC4R pathway β-MSH activates is pharmacologically tractable in humans.
- Animal: Harrold and colleagues (Peptides, 2003) showed that β-MSH binds the rat MC4R with a Ki of 5.0 nmol/L and significantly increases hypothalamic G-protein activation in rat brain slices. Harno and colleagues (Physiological Reviews, 2018) noted that exogenous β-MSH reduces food intake in corticosterone-supplemented Pomc-null mice. Møller and colleagues (BMC Research Notes, 2015) found that melanocortin agonists stimulate lipolysis in human adipose tissue explants, though not in isolated adipocytes, suggesting tissue-context-dependent metabolic effects.
- In vitro: Binding assays at the human MC4R showed β-MSH affinity (Ki = 11.4 nmol/L) approximately 28-fold greater than α-MSH (Ki = 324 nmol/L) (Harrold and colleagues 2003). Ericson and colleagues (2017) noted that β-MSH shows approximately 30-fold higher potency at the human MC4R and 4-fold higher potency at the rat MC4R compared to α-MSH.
Known effects
- Appetite suppression / reduction of food intake — Demonstrated in animal models and inferred from human genetic loss-of-function data (Harrold and colleagues 2003; Lee and colleagues 2006); preclinical evidence
- MC4R activation and energy expenditure — Indirect human evidence via pharmacological MC4R agonism (Chen K and colleagues 2015); Phase I/II data for synthetic agonists
- Regulation by nutritional state — Hypothalamic β-MSH rises during food restriction in rats (Harrold and colleagues 2003); preclinical
- Lipolysis in adipose tissue — Melanocortin agonists stimulate lipolysis in human adipose explants (Møller and colleagues 2015); ex vivo human data
- Intestinal satiety hormone release — MC4R in enteroendocrine L cells regulates PYY and GLP-1 secretion (Panaro and colleagues 2014); preclinical/in vivo
Safety signals
β-MSH itself has not been evaluated in clinical trials. Safety information derives from the broader melanocortin system and from synthetic MC4R agonists. The most consistent adverse effects seen with MC4R agonists in trials include hyperpigmentation (due to MC1R cross-reactivity at higher doses), nausea, and injection-site reactions (reported in setmelanotide Phase III trials). Transient increases in blood pressure have been noted with some MC4R agonists and have influenced drug development strategy. These signals are reported for synthetic agonists, not for endogenous β-MSH itself.
Regulatory status
β-MSH is an endogenous peptide with no regulatory classification as a drug. It is used as a research tool. Synthetic analogs targeting the same MC4R pathway — setmelanotide (IMCIVREE, FDA-approved 2020 for POMC/PCSK1/LEPR deficiency obesity, extended to Bardet-Biedl syndrome 2022) and bremelanotide (Vyleesi, FDA-approved 2019 for hypoactive sexual desire disorder in premenopausal women) — are approved clinical agents. β-MSH itself has no WADA classification. Research use of synthetic β-MSH is unrestricted.
Mechanism
β-MSH is a 22-residue peptide cleaved from the C-terminal region of γ-lipotropin (γ-LPH), which is itself a fragment of β-lipotropin (β-LPH), via prohormone convertase action at a dibasic Lys-Lys site present in human POMC but absent in rodent POMC (Harno and colleagues 2018; Ericson and colleagues 2017). The sequence AEKKDEGPYRMEHFRWGSPPKD lacks the N-terminal acetyl and C-terminal amide modifications carried by α-MSH; the shared core pharmacophore His-Phe-Arg-Trp (HFRW) at positions 14–17 of this sequence is the motif that engages the melanocortin receptor binding pocket. β-MSH binds MC4R with substantially higher affinity than α-MSH — Ki ~11 nmol/L vs ~324 nmol/L at the human receptor (Harrold and colleagues 2003) — and activates Gαs-coupled adenylyl cyclase to increase intracellular cAMP in MC4R-expressing neurons. The hypothalamic MC4R neurons that respond to β-MSH, concentrated in the paraventricular nucleus, are part of the leptin–melanocortin axis: POMC neurons in the arcuate nucleus are activated by leptin and release melanocortin ligands (including β-MSH) onto downstream MC4R neurons to suppress feeding and increase energy expenditure. β-MSH also shows moderate affinity at MC3R, which is expressed at lower levels in the hypothalamus and may modulate feedback within the POMC circuit. The peripheral action via MC4R in enteroendocrine L cells, stimulating PYY and GLP-1 release (Panaro and colleagues 2014), adds a gut-brain component to its anorexigenic profile. Chen and colleagues (2009) characterized the contribution of transmembrane domain 6 of MC4R to peptide selectivity, showing structural determinants at this region influence ligand discrimination between MC3R and MC4R.
Related peptides
- α-MSH — the other major POMC-derived melanocortin ligand; 13 amino acids, N-terminally acetylated and C-terminally amidated; the reference agonist for MC4R signaling and the parent compound from which analogs such as PT-141 (bremelanotide) were developed
- Setmelanotide — synthetic cyclic octapeptide MC4R agonist approved for rare genetic obesity caused by POMC, PCSK1, or LEPR pathway deficiency; the clinical descendant of the MC4R pharmacology that β-MSH exemplifies
- PT-141 / bremelanotide — synthetic cyclic MC3R/MC4R agonist derived from α-MSH; FDA-approved for hypoactive sexual desire disorder; shares the MC4R pathway activated by β-MSH in sexual function circuitry
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does the charged front end of beta-MSH steer the peptide toward the weight-control receptor rather than the skin-pigment receptor?
If true, drug designers could shorten beta-MSH to a version that hits only the appetite-control receptor, potentially making weight-loss medicines with fewer side effects for patients with obesity caused by faulty POMC signaling.
For people whose bodies cannot make beta-MSH due to a genetic mutation, would replacing this specific peptide work better than drugs designed in mice?
If true, patients with a specific genetic obesity caused by broken beta-MSH production could benefit from a replacement therapy that matches their exact deficiency, potentially with fewer hormonal side effects than current treatments.
Could this appetite hormone also act inside the gut lining to reduce inflammation or control fluid secretion?
If beta-MSH works in the gut as well as the brain, it might be developed as a treatment for inflammatory bowel disease or chronic diarrhea, conditions that currently have limited effective therapies.
Does the rigid bend near the tail of beta-MSH create a second contact point with the appetite receptor?
If this bend acts as a second anchor, scientists could use it as an engineering target to create longer-lasting versions of beta-MSH, which could help develop better treatments for inherited obesity conditions.
Do the charged building blocks near the front of beta-MSH snap it into a shape that could steer it toward the weight-control receptor?
If this self-shaping effect proves real, chemists could try locking beta-MSH into that shape, which might yield a more selective drug candidate for appetite disorders.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.8786473274230957 | boltz-2 |
| ranking score | 0.825774610042572 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.616 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep10489,
sequence = {AEKKDEGPYRMEHFRWGSPPKD},
target = {mc4r},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}